180 related articles for article (PubMed ID: 24740199)
1. Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.
Block MS; Charbonneau B; Vierkant RA; Fogarty Z; Bamlet WR; Pharoah PD; ; ; ; Rossing MA; Cramer D; Pearce CL; Schildkraut J; Menon U; Kjaer SK; Levine DA; Gronwald J; Culver HA; Whittemore AS; Karlan BY; Lambrechts D; Wentzensen N; Kupryjanczyk J; Chang-Claude J; Bandera EV; Hogdall E; Heitz F; Kaye SB; Fasching PA; Campbell I; Goodman MT; Pejovic T; Bean YT; Hays LE; Lurie G; Eccles D; Hein A; Beckmann MW; Ekici AB; Paul J; Brown R; Flanagan JM; Harter P; du Bois A; Schwaab I; Hogdall CK; Lundvall L; Olson SH; Orlow I; Paddock LE; Rudolph A; Eilber U; Dansonka-Mieszkowska A; Rzepecka IK; Ziolkowska-Seta I; Brinton LA; Yang H; Garcia-Closas M; Despierre E; Lambrechts S; Vergote I; Walsh CS; Lester J; Sieh W; McGuire V; Rothstein JH; Ziogas A; Lubiński J; Cybulski C; Menkiszak J; Jensen A; Gayther SA; Ramus SJ; Gentry-Maharaj A; Berchuck A; Wu AH; Pike MC; Van Den Berg D; Terry KL; Vitonis AF; Ramirez SM; Rider DN; Knutson KL; Sellers TA; Phelan CM; Doherty JA; Johnatty SE; deFazio A; Song H; Tyrer J; Kalli KR; Fridley BL; Cunningham JM; Goode EL
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1421-7. PubMed ID: 24740199
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
4. The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.
Li Z; Block MS; Vierkant RA; Fogarty ZC; Winham SJ; Visscher DW; Kalli KR; Wang C; Goode EL
Tumour Biol; 2016 Oct; 37(10):13279-13286. PubMed ID: 27460076
[TBL] [Abstract][Full Text] [Related]
5. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
Dutta S; Wang FQ; Wu HS; Mukherjee TJ; Fishman DA
Gynecol Oncol; 2011 Oct; 123(1):129-37. PubMed ID: 21782227
[TBL] [Abstract][Full Text] [Related]
6. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.
Hampras SS; Sucheston-Campbell LE; Cannioto R; Chang-Claude J; Modugno F; Dörk T; Hillemanns P; Preus L; Knutson KL; Wallace PK; Hong CC; Friel G; Davis W; Nesline M; Pearce CL; Kelemen LE; Goodman MT; Bandera EV; Terry KL; Schoof N; Eng KH; Clay A; Singh PK; Joseph JM; Aben KK; Anton-Culver H; Antonenkova N; Baker H; Bean Y; Beckmann MW; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bruinsma F; Butzow R; Campbell IG; Carty K; Cook LS; Cramer DW; Cybulski C; Dansonka-Mieszkowska A; Dennis J; Despierre E; Dicks E; Doherty JA; du Bois A; Dürst M; Easton D; Eccles D; Edwards RP; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Gronwald J; Harrington P; Harter P; Hasmad HN; Hein A; Heitz F; Hildebrandt MA; Hogdall C; Hogdall E; Hosono S; Iversen ES; Jakubowska A; Jensen A; Ji BT; Karlan BY; Kellar M; Kelley JL; Kiemeney LA; Klapdor R; Kolomeyevskaya N; Krakstad C; Kjaer SK; Kruszka B; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lissowska J; Liu S; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; McNeish I; Menon U; Moes-Sosnowska J; Narod SA; Nedergaard L; Nevanlinna H; Nickels S; Olson SH; Orlow I; Weber RP; Paul J; Pejovic T; Pelttari LM; Perkins B; Permuth-Wey J; Pike MC; Plisiecka-Halasa J; Poole EM; Risch HA; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schernhammer E; Schmitt K; Schwaab I; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Tangen IL; Teo SH; Thompson PJ; Timorek A; Tsai YY; Tworoger SS; Tyrer J; van Altena AM; Vergote I; Vierkant RA; Walsh C; Wang-Gohrke S; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Wu AH; Wu X; Woo YL; Yang H; Zheng W; Ziogas A; Gayther SA; Ramus SJ; Sellers TA; Schildkraut JM; Phelan CM; Berchuck A; Chenevix-Trench G; Cunningham JM; Pharoah PP; Ness RB; Odunsi K; Goode EL; Moysich KB
Oncotarget; 2016 Oct; 7(43):69097-69110. PubMed ID: 27533245
[TBL] [Abstract][Full Text] [Related]
7. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk.
Chornokur G; Lin HY; Tyrer JP; Lawrenson K; Dennis J; Amankwah EK; Qu X; Tsai YY; Jim HS; Chen Z; Chen AY; Permuth-Wey J; Aben KK; Anton-Culver H; Antonenkova N; Bruinsma F; Bandera EV; Bean YT; Beckmann MW; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bunker CH; Butzow R; Campbell IG; Carty K; Chang-Claude J; Cook LS; Cramer DW; Cunningham JM; Cybulski C; Dansonka-Mieszkowska A; du Bois A; Despierre E; Dicks E; Doherty JA; Dörk T; Dürst M; Easton DF; Eccles DM; Edwards RP; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Goodman MT; Gronwald J; Harrington P; Harter P; Hein A; Heitz F; Hildebrandt MA; Hillemanns P; Hogdall CK; Hogdall E; Hosono S; Jakubowska A; Jensen A; Ji BT; Karlan BY; Kelemen LE; Kellar M; Kiemeney LA; Krakstad C; Kjaer SK; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lim BK; Lissowska J; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; McNeish I; Menon U; Milne RL; Modugno F; Moysich KB; Ness RB; Nevanlinna H; Eilber U; Odunsi K; Olson SH; Orlow I; Orsulic S; Weber RP; Paul J; Pearce CL; Pejovic T; Pelttari LM; Pike MC; Poole EM; Risch HA; Rosen B; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schernhammer E; Schwaab I; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Spiewankiewicz B; Sucheston L; Teo SH; Terry KL; Thompson PJ; Thomsen L; Tangen IL; Tworoger SS; van Altena AM; Vierkant RA; Vergote I; Walsh CS; Wang-Gohrke S; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Wu AH; Wu X; Woo YL; Yang H; Zheng W; Ziogas A; Hasmad HN; Berchuck A; ; ; Iversen ES; Schildkraut JM; Ramus SJ; Goode EL; Monteiro AN; Gayther SA; Narod SA; Pharoah PD; Sellers TA; Phelan CM
PLoS One; 2015; 10(6):e0128106. PubMed ID: 26091520
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
9. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
10. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
[TBL] [Abstract][Full Text] [Related]
11. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
12. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
13. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes.
Cuellar-Partida G; Lu Y; Dixon SC; ; Fasching PA; Hein A; Burghaus S; Beckmann MW; Lambrechts D; Van Nieuwenhuysen E; Vergote I; Vanderstichele A; Doherty JA; Rossing MA; Chang-Claude J; Rudolph A; Wang-Gohrke S; Goodman MT; Bogdanova N; Dörk T; Dürst M; Hillemanns P; Runnebaum IB; Antonenkova N; Butzow R; Leminen A; Nevanlinna H; Pelttari LM; Edwards RP; Kelley JL; Modugno F; Moysich KB; Ness RB; Cannioto R; Høgdall E; Høgdall C; Jensen A; Giles GG; Bruinsma F; Kjaer SK; Hildebrandt MA; Liang D; Lu KH; Wu X; Bisogna M; Dao F; Levine DA; Cramer DW; Terry KL; Tworoger SS; Stampfer M; Missmer S; Bjorge L; Salvesen HB; Kopperud RK; Bischof K; Aben KK; Kiemeney LA; Massuger LF; Brooks-Wilson A; Olson SH; McGuire V; Rothstein JH; Sieh W; Whittemore AS; Cook LS; Le ND; Blake Gilks C; Gronwald J; Jakubowska A; Lubiński J; Kluz T; Song H; Tyrer JP; Wentzensen N; Brinton L; Trabert B; Lissowska J; McLaughlin JR; Narod SA; Phelan C; Anton-Culver H; Ziogas A; Eccles D; Campbell I; Gayther SA; Gentry-Maharaj A; Menon U; Ramus SJ; Wu AH; Dansonka-Mieszkowska A; Kupryjanczyk J; Timorek A; Szafron L; Cunningham JM; Fridley BL; Winham SJ; Bandera EV; Poole EM; Morgan TK; Goode EL; Schildkraut JM; Pearce CL; Berchuck A; Pharoah PD; Webb PM; Chenevix-Trench G; Risch HA; MacGregor S
Hum Genet; 2016 Jul; 135(7):741-56. PubMed ID: 27075448
[TBL] [Abstract][Full Text] [Related]
14. Prediction value of intercellular adhesion molecule-1 gene polymorphisms for epithelial ovarian cancer risk, clinical features, and prognosis.
Cai G; Ma X; Zou W; Huang Y; Zhang J; Wang D; Chen B
Gene; 2014 Aug; 546(1):117-23. PubMed ID: 23933413
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic significance of microRNA-451 in human epithelial ovarian cancer.
Ling S; Ruiqin M; Guohong Z; Ying W
Eur J Gynaecol Oncol; 2015; 36(4):463-8. PubMed ID: 26390704
[TBL] [Abstract][Full Text] [Related]
16. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.
Hedditch EL; Gao B; Russell AJ; Lu Y; Emmanuel C; Beesley J; Johnatty SE; Chen X; Harnett P; George J; ; Williams RT; Flemming C; Lambrechts D; Despierre E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching P; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Nakanishi T; Yatabe Y; Pejovic T; Bean Y; Heitz F; Harter P; du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan J; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut J; Iversen E; Weber RP; Berchuck A; Goode E; Bowtell DD; Chenevix-Trench G; deFazio A; Norris MD; MacGregor S; Haber M; Henderson MJ
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957074
[TBL] [Abstract][Full Text] [Related]
17. Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.
Ma M; Yu N
Tohoku J Exp Med; 2017 Mar; 241(3):239-247. PubMed ID: 28344213
[TBL] [Abstract][Full Text] [Related]
18. Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
Sahin H; Meydanli MM; Sari ME; Yalcin I; Çoban G; Ozkan NT; Cuylan ZF; Erdem B; Gungorduk K; Akbayir Ö; Dede M; Salman MC; Güngör T; Ayhan A
J Ovarian Res; 2018 Mar; 11(1):21. PubMed ID: 29506569
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
Ma Z; Wang X; He J; Xia J; Li Y
PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
Mackay HJ; Brady MF; Oza AM; Reuss A; Pujade-Lauraine E; Swart AM; Siddiqui N; Colombo N; Bookman MA; Pfisterer J; du Bois A;
Int J Gynecol Cancer; 2010 Aug; 20(6):945-52. PubMed ID: 20683400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
